American Society of Hematology @ash.hematology.org · Jun 3 New research published in Blood found that stem cell transplantation was the most cost-effective treatment option for adults living with sickle cell disease compared with gene therapy and standard of care. Read more 🔗 https://ow.ly/eiQj50Z7aPU #HemeSky #ConquerSCD Blood Journals Portfolio
1 likes 1 replies
?
Replies
Cost-effectiveness analyses depend heavily on the time horizon and discount rate chosen — was this based on lifetime horizon, and if so, how were long-term graft failure and malignancy risks modeled?